Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry

American Journal of Medicine

Volumn 113, Issue 2, 2002, Pages 112-119

  Weinreb, Neal J ^a,k   Charrow, Joel ^b   Andersson, Hans C ^c   Kaplan, Paige ^d   Kolodny, Edwin H ^e   Mistry, Pramod ^f   Pastores, Gregory ^e   Rosenbloom, Barry E ^g   Scott, C Ronald ^h   Wappner, Rebecca S ⁱ   Zimran, Ari ^j  

^a University Hospital   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j SHAARE ZEDEK MEDICAL CENTER   (Israel)

^k University Gaucher Treatment Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; HEMOGLOBIN; IMIGLUCERASE;

ADULT; ANEMIA; ARTICLE; BONE PAIN; DISEASE COURSE; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEPATOMEGALY; HUMAN; LIVER SIZE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; MALE; PAIN MEASUREMENT; PLATELET COUNT; REGISTRIES; RISK ASSESSMENT; SPLEEN; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037159549     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01150-6     Document Type: Article

References (43)

1. Metabolism of glucocerebrosides, II: Evidence of an enzymatic deficiency in Gaucher disease
2. Glucosylceramide lipidoses: Gaucher disease
3. Enzyme therapy in Gaucher disease type 1: Comparative efficacy of mannose-terminated-glucocerebrosidase from natural and recombinant sources
4. Replacement therapy for inherited enzyme deficiency: Macrophage-targeted glucocerebrosidase for Gaucher's disease
5. Enzyme replacement therapy in Gaucher disease type 1: Skeletal responses to macrophage-targeted glucocerebrosidase
6. The Gaucher Registry: Demographics and disease characteristics of 1698 patients with Gaucher disease
7. Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: Comparison to computed tomographic measurements
8. Enzyme augmentation in moderate to life-threatening Gaucher disease
9. A less costly regimen of alglucerase to treat Gaucher's disease
10. Treatment of Gaucher's disease
11. Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months
12. Type I Gaucher's disease: Clinical, evolutive and therapeutic features in 8 cases
13. Low-dose enzyme replacement therapy for Gaucher's disease: Effects of age, sex, genotype, and clinical features on response to treatment
14. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease
15. Glucocerebrosidase for treatment of Gaucher's disease: First German long-term results
16. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease
17. Replacement therapy with imiglucerase for type 1 Gaucher's disease
18. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase
19. Enzyme replacement therapy: A new treatment concept in Gaucher disease
20. Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease
21. Clinical and molecular aspects of Gaucher disease in New Zealand
22. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease
23. First long-term results of imiglucerase therapy of type 1 Gaucher disease
24. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease
25. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration
26. Gaucher disease type 1 - Therapeutic results of enzyme substitution
27. Enzyme replacement therapy for Gaucher's disease: The early Canadian experience
28. Gaucher patients treated at HEMORIO
29. Enzyme therapy for Gaucher disease: The first 5 years
30. Novel oral treatment of Gaucher's disease with N-butyl deoxynojirimycin (OGT 918) to decrease substrate biosynthesis
31. Agents for the treatment of glycosphingolipid storage disorders
32. Splenectomy in Gaucher disease: New management dilemmas
33. Liver abnormalities in patients with Gaucher's disease
34. Gaucher's disease: Clinical features and natural history
35. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics
36. Hepatopulmonary syndrome: An evolving perspective in the era of liver transplantation
37. The pathology of Gaucher disease: A Century of Delineation and Research
38. Gaucher's disease: A pilot study of the symptomatic responses to enzyme replacement therapy
39. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement
40. The clinical course of treated and untreated Gaucher disease. A study of 45 patients
41. Low-dose high frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type 1 Gaucher disease
42. Lower-dose, high-frequency enzyme replacement therapy in children with type 1 Gaucher disease: Experience at the Schneider Children's Medical Center of Israel
43. Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring